COR-1, an Anti-Beta1 Receptor Antibody Cyclopeptide in Heart Failure: a Phase II, Multicentre, Randomised, Double-Blind and Placebo-Controlled Study With Parallel Groups.

Trial Profile

COR-1, an Anti-Beta1 Receptor Antibody Cyclopeptide in Heart Failure: a Phase II, Multicentre, Randomised, Double-Blind and Placebo-Controlled Study With Parallel Groups.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2017

At a glance

  • Drugs Mibenratide (Primary)
  • Indications Dilated cardiomyopathy; Heart failure
  • Focus Therapeutic Use
  • Sponsors Corimmun
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Mar 2013 Planned End Date changed from 1 Sep 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top